# Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

> **NCT04595370** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 153 (actual)

## Conditions studied

- Heart Failure
- Chronic Kidney Disease

## Interventions

- **DRUG:** AZD9977
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT04595370
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-22
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04595370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04595370, "Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04595370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*